Phuturdex › Diseases › Neuromuscular disease
Drugs in development · updated 30 October 2026
Neuromuscular disease: drugs in development
As of 30 October 2026 there are 15 active clinical trials (recruiting or ongoing, phases I–III) on 14 drugs for neuromuscular disease. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AOC 1044 | III | 1 | NCT07587242 |
| Deramiocel | III | 1 | NCT05126758 |
| Taldefgrobep Alfa | III | 1 | NCT05337553 |
| Zeleciment Rostudirsen | III | 1 | NCT07608432 |
| VX-670 | I–II | 2 | NCT06185764 |
| AB-1009 | I–II | 1 | NCT07282847 |
| AFA-281 | II | 1 | NCT06649747 |
| SAT-3247 | II | 1 | NCT07287189 |
| VCA-894A | I–II | 1 | NCT07223632 |
| ATI-105 | I | 1 | NCT07869654 |
| AZD5492 | I | 1 | NCT06916806 |
| SNUG01 | Early I | 1 | NCT06645197 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ApitegromabIsembyld® | III | 1 | NCT05626855 |
| RiluzoleExservan®, Tiglutik Kit® | I | 1 | NCT07093268 |
Sorted by most advanced phase and number of active trials.
All 14 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Amyotrophic lateral sclerosis 79 drugs
- Myasthenia gravis 49 drugs
- Duchenne muscular dystrophy 35 drugs
- Myositis 42 drugs
- Neurofibromatosis 1 28 drugs
- Systemic scleroderma 77 drugs
- Systemic lupus erythematosus 178 drugs
- Dermatomyositis 52 drugs
- Chronic inflammatory demyelinating polyradiculoneuropathy 23 drugs
- Neuralgia 21 drugs
- Neurofibrosarcoma 24 drugs
- Autoimmune disease 94 drugs
Broader categories
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Nervous System Diseases 39 drugs
- Neurodegenerative Diseases 25 drugs
- Central nervous system disease 38 drugs
- Spinal cord disease 6 drugs
- Nervous system heredodegenerative disease 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009468 “Neuromuscular Diseases”.